



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁵ : A61M 31/00	A2	(11) International Publication Number: WO 93/14807 (43) International Publication Date: 5 August 1993 (05.08.93)
(21) International Application Number: PCT/US93/00676 (22) International Filing Date: 19 January 1993 (19.01.93) (30) Priority data: 07/830,304 31 January 1992 (31.01.92) US (71) Applicant: GENSLA, INC. [US/US]; 11025 Roselle Street, San Diego, CA 92121 (US). (72) Inventors: VALCKE, Christian, Paul ; 10667 Wilkins Avenue #2, Los Angeles, CA 90024 (US). BOCHENKO, Walter, John ; 2258 9th Street, Encinitas, CA 92024 (US). HILLMAN, Robert, Steven ; 13134 Janetta Place, San Diego, CA 92130 (US).		(74) Agents: MURPHY, David, B. et al.; Lyon & Lyon, 611 West 6th Street, 34th Floor, Los Angeles, CA 90017 (US). (81) Designated States: CA, FI, JP, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: METHOD AND APPARATUS FOR CLOSED LOOP DRUG DELIVERY (57) Abstract A closed-loop drug delivery system uses patient response and rule based decision making methods to achieve operator specified responses for diagnostic purposes. In the preferred embodiment, cardiac diagnosis is performed by pharmacologically stressing the heart by administration of an exercise simulating agent drug. In the preferred method, a protocol is defined, which preferably includes a target for a physiologic variable, such as heart rate, and a plan to achieve that target value. Preferably, the plan includes a specification of the desired rate of increase in that variable, such as the rate of increase in the heart rate per minute. The plan comprises the desired changes in the physiologic variable as a function of time. While any desired function may be used, the more common modes include RAMP, HOLD, LEVEL and TARGET mode. In one aspect of this invention, the protocol may be varied by the operator after drug administration has begun. Further, in one embodiment, the protocol includes a definition of an acceptable zone of deviation from the plan, such that if the patient physiologic variable deviates from the permissible zone, alternate control rules are implemented. Preferably, saturation detection and avoidance is implemented.		



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61M 31/00		A3	(11) International Publication Number: WO 93/14807
			(43) International Publication Date: 5 August 1993 (05.08.93)
(21) International Application Number: PCT/US93/00676		(74) Agents: MURPHY, David, B. et al.; Lyon & Lyon, 611 West 6th Street, 34th Floor, Los Angeles, CA 90017 (US).	
(22) International Filing Date: 19 January 1993 (19.01.93)			
(30) Priority data: 07/830,304 31 January 1992 (31.01.92) US		(81) Designated States: CA, FI, JP, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(71) Applicant: GENSIA, INC. [US/US]; 11025 Roselle Street, San Diego, CA 92121 (US).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors: VALCKE, Christian, Paul ; 10667 Wilkins Avenue #2, Los Angeles, CA 90024 (US). BOCHENKO, Walter, John ; 2258 9th Street, Encinitas, CA 92024 (US). HILLMAN, Robert, Steven ; 13134 Janetta Place, San Diego, CA 92130 (US).		(88) Date of publication of the international search report: 08 December 1994 (08.12.94)	

(54) Title: METHOD AND APPARATUS FOR CLOSED LOOP DRUG DELIVERY



(57) Abstract

A closed loop drug delivery system uses patient response and rule based decision making methods to achieve operator specified responses for diagnostic purposes. Cardiac diagnosis is performed by pharmacologically stressing the heart by administration of an exercise simulating drug. A protocol is defined, which includes a target for a physiologic variable, such as heart rate, and a plan to achieve that target value. The plan includes a specification of the desired rate of increase in that variable, such as the rate of increase in the heart rate per minute. The plan comprises the desired changes in the physiologic variable as a function of time. While any desired function may be used, the more common modes include RAMP, HOLD, LEVEL and TARGET mode. The protocol may be varied by the operator after drug administration has begun. Further, the protocol includes a definition of an acceptable zone of deviation from the plan.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MD	Republic of Moldova	TJ	Tajikistan
DE	Germany	MG	Madagascar	TT	Trinidad and Tobago
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain	MN	Mongolia	US	United States of America
FI	Finland			UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/00676

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61M 31/00

US CL :604/66

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 604/65-67; 128/Dig.12, Dig.13

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS: Exercise (W) Stimulating (W) agent?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---, P Y	US, A, 5,108,363 (Tuttle et al.) 28 April 1992. See entire document.	1-9, 12, 13, 16-37, 39-50, 52-66 and 68-70 ----- 10, 11, 14, 15, 38, 51, 67
Y	US, A, 4,871,351 (Feingold) 03 October 1989. See column 2, line 33 - column 3, line 23.	1-70
A	US, A, 4,718,891 (Lipps) 12 January 1988. See Abstract.	1-70

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	A	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 May 1993

Date of mailing of the international search report

25 OCT 1994

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Authorized officer

 FOR *Allen Strayer*
 Ralph Lewis

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-1320

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/00676

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,551,133 (Zegers de Beyl et al.) 05 November 1985. See Abstract.	1-70
A	US, A, 4,533,346 (Cosgrove, Jr. et al.) 06 August 1985. See Abstract.	1-70
A	US, A, 4,392,849 (Petre et al.) 12 July 1983. See Abstract.	1-70